What is Surmodics?
Surmodics is recognized as a global leader in the specialized field of surface modification technologies, primarily serving the intravascular medical device sector. The company also plays a crucial role as a provider of essential chemical components for in vitro diagnostic (IVD) immunoassay tests and microarrays. Beyond its core component offerings, Surmodics actively designs and produces highly differentiated, complete medical devices aimed at addressing unmet clinical needs within intravascular medicine. This dual focus on advanced materials science and integrated device solutions positions Surmodics at the forefront of medical technology innovation.
How much funding has Surmodics raised?
Surmodics has raised a total of $140M across 2 funding rounds:
Stock Offering
$15M
Debt
$125M
Stock Issuance/Offering (1998): $15M, investors not publicly disclosed
Debt (2022): $125M led by MidCap Financial
Key Investors in Surmodics
MidCap Financial
MidCap Financial is a provider of flexible financing solutions, specializing in quickly and efficiently addressing opportunities to support business growth.
What's next for Surmodics?
The recent major strategic investment signals a pivotal moment for Surmodics, likely enabling accelerated development of its advanced surface modification technologies and intravascular medical devices. This capital infusion is expected to fuel expansion into new markets, enhance research and development capabilities, and potentially support strategic acquisitions. Surmodics' focus on addressing unmet clinical needs suggests a trajectory geared towards scaling its product pipeline and solidifying its market leadership through continued technological advancement and strategic partnerships.
See full Surmodics company page
